6 July 2022 - Application is based on results from the pivotal Phase I/II study showing mosunetuzumab induced high and durable complete response rates in people with follicular lymphoma who received two or more prior therapies.
Genentech today announced that the U.S. FDA has accepted the company’s biologics license application and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.